GB2173798A - Cephalosporanic acid derivatives - Google Patents
Cephalosporanic acid derivatives Download PDFInfo
- Publication number
- GB2173798A GB2173798A GB08609661A GB8609661A GB2173798A GB 2173798 A GB2173798 A GB 2173798A GB 08609661 A GB08609661 A GB 08609661A GB 8609661 A GB8609661 A GB 8609661A GB 2173798 A GB2173798 A GB 2173798A
- Authority
- GB
- United Kingdom
- Prior art keywords
- compound
- cephem
- amino
- lithium
- propen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- YGBFLZPYDUKSPT-MRVPVSSYSA-N cephalosporanic acid Chemical class S1CC(COC(=O)C)=C(C(O)=O)N2C(=O)C[C@H]21 YGBFLZPYDUKSPT-MRVPVSSYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 25
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- 239000002253 acid Substances 0.000 claims abstract description 13
- 239000001257 hydrogen Substances 0.000 claims abstract description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 8
- 229910052751 metal Inorganic materials 0.000 claims abstract description 7
- 239000002184 metal Substances 0.000 claims abstract description 7
- 239000000126 substance Substances 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 37
- 239000000203 mixture Substances 0.000 claims description 28
- -1 2-(trimethylsilyl)ethyl Chemical group 0.000 claims description 20
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 17
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 16
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 claims description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 11
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- 229910052744 lithium Inorganic materials 0.000 claims description 4
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical group [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 claims description 4
- HSZCZNFXUDYRKD-UHFFFAOYSA-M lithium iodide Chemical compound [Li+].[I-] HSZCZNFXUDYRKD-UHFFFAOYSA-M 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- 239000011591 potassium Substances 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 claims description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 238000002474 experimental method Methods 0.000 claims description 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 2
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 claims description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000012430 organic reaction media Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 claims 1
- 229930186147 Cephalosporin Natural products 0.000 abstract description 10
- 229940124587 cephalosporin Drugs 0.000 abstract description 10
- 150000001780 cephalosporins Chemical class 0.000 abstract description 7
- 238000002360 preparation method Methods 0.000 abstract description 7
- 239000000543 intermediate Substances 0.000 abstract description 4
- 150000002148 esters Chemical class 0.000 abstract description 3
- UBXPJNKEFJVBII-ZTHSNPKKSA-N (6R)-3-[(Z)-2-aminoprop-1-enyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N\C(=C/C=1CS[C@H]2N(C=1C(=O)O)C(C2)=O)\C UBXPJNKEFJVBII-ZTHSNPKKSA-N 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 36
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- 239000000243 solution Substances 0.000 description 21
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 16
- 235000019439 ethyl acetate Nutrition 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 238000001914 filtration Methods 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 8
- 235000019341 magnesium sulphate Nutrition 0.000 description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 8
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 7
- 239000008363 phosphate buffer Substances 0.000 description 7
- 239000002002 slurry Substances 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 5
- 239000003610 charcoal Substances 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 4
- 238000007239 Wittig reaction Methods 0.000 description 4
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- XFIMQDGBHJULGY-WFDQOPGTSA-N (6r,7r)-7-[[(2r)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(z)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)\C=C/C)C(O)=O)=CC=C(O)C=C1.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)\C=C/C)C(O)=O)=CC=C(O)C=C1 XFIMQDGBHJULGY-WFDQOPGTSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- 230000010933 acylation Effects 0.000 description 3
- 238000005917 acylation reaction Methods 0.000 description 3
- AEECHDKJQFHHEH-YFVGKJKASA-N benzhydryl (6R)-7-(benzylideneamino)-8-oxo-3-[(triphenyl-lambda5-phosphanylidene)methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound C(C1=CC=CC=C1)=NC1[C@@H]2N(C(=C(CS2)C=P(C2=CC=CC=C2)(C2=CC=CC=C2)C2=CC=CC=C2)C(=O)OC(C2=CC=CC=C2)C2=CC=CC=C2)C1=O AEECHDKJQFHHEH-YFVGKJKASA-N 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 125000006238 prop-1-en-1-yl group Chemical group [H]\C(*)=C(/[H])C([H])([H])[H] 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 2
- YSULOORXQBDPCU-UHFFFAOYSA-N 2-(trimethylazaniumyl)ethanehydrazonate;hydrochloride Chemical compound [Cl-].C[N+](C)(C)CC(=O)NN YSULOORXQBDPCU-UHFFFAOYSA-N 0.000 description 2
- LJCWONGJFPCTTL-UHFFFAOYSA-N 4-hydroxyphenylglycine Chemical compound OC(=O)C(N)C1=CC=C(O)C=C1 LJCWONGJFPCTTL-UHFFFAOYSA-N 0.000 description 2
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- MRFJAULKKHVIGF-OGFXRTJISA-N (2r)-2-amino-2-(4-hydroxyphenyl)acetyl chloride;hydrochloride Chemical compound Cl.ClC(=O)[C@H](N)C1=CC=C(O)C=C1 MRFJAULKKHVIGF-OGFXRTJISA-N 0.000 description 1
- WDLWHQDACQUCJR-HTCLMOQTSA-N (6R)-7-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-prop-1-enyl-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N[C@@H](C(=O)NC1[C@@H]2N(C(=C(CS2)C=CC)C(=O)O)C1=O)C1=CC=C(C=C1)O WDLWHQDACQUCJR-HTCLMOQTSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- WCBVOPMSONYWEB-UHFFFAOYSA-N 2-aminoacetyl chloride Chemical compound NCC(Cl)=O WCBVOPMSONYWEB-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- IFQUPKAISSPFTE-UHFFFAOYSA-N 4-benzoylbenzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C(=O)C1=CC=CC=C1 IFQUPKAISSPFTE-UHFFFAOYSA-N 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- FCSKOFQQCWLGMV-UHFFFAOYSA-N 5-{5-[2-chloro-4-(4,5-dihydro-1,3-oxazol-2-yl)phenoxy]pentyl}-3-methylisoxazole Chemical compound O1N=C(C)C=C1CCCCCOC1=CC=C(C=2OCCN=2)C=C1Cl FCSKOFQQCWLGMV-UHFFFAOYSA-N 0.000 description 1
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- BEFRBWFJHVPLLP-BOIJOYFTSA-N Cl.C1(=CC=CC=C1)C(C1=CC=CC=C1)C1S[C@H]2N(C(=C1\C=C/C)C(=O)O)C(C2N)=O Chemical compound Cl.C1(=CC=CC=C1)C(C1=CC=CC=C1)C1S[C@H]2N(C(=C1\C=C/C)C(=O)O)C(C2N)=O BEFRBWFJHVPLLP-BOIJOYFTSA-N 0.000 description 1
- 241001379910 Ephemera danica Species 0.000 description 1
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 1
- 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 1
- 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 1
- GRMFXNQIRFLDLC-RQRXLDSQSA-M [(6R)-2-benzhydryloxycarbonyl-7-(benzylideneamino)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl-triphenylphosphanium chloride Chemical compound [Cl-].C(C1=CC=CC=C1)=NC1[C@@H]2N(C(=C(CS2)C[P+](C2=CC=CC=C2)(C2=CC=CC=C2)C2=CC=CC=C2)C(=O)OC(C2=CC=CC=C2)C2=CC=CC=C2)C1=O GRMFXNQIRFLDLC-RQRXLDSQSA-M 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000004849 alkoxymethyl group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- HDYOATPRFNMLSX-ALAWQYECSA-N benzhydryl (6r)-7-amino-3-(chloromethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate;hydrochloride Chemical compound Cl.S([C@@H]1C(C(N11)=O)N)CC(CCl)=C1C(=O)OC(C=1C=CC=CC=1)C1=CC=CC=C1 HDYOATPRFNMLSX-ALAWQYECSA-N 0.000 description 1
- KGHADALWBFAJHM-SOSCOHMFSA-N benzhydryl (6r)-7-amino-8-oxo-3-[(z)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound S([C@H]1N2C(C1N)=O)CC(\C=C/C)=C2C(=O)OC(C=1C=CC=CC=1)C1=CC=CC=C1 KGHADALWBFAJHM-SOSCOHMFSA-N 0.000 description 1
- QMFDHRBUUPBCQU-UQYHSIEJSA-N benzhydryl (6r)-8-oxo-7-[(2-phenylacetyl)amino]-3-[(z)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound C1([C@@H]2N(C1=O)C(=C(CS2)\C=C/C)C(=O)OC(C=1C=CC=CC=1)C=1C=CC=CC=1)NC(=O)CC1=CC=CC=C1 QMFDHRBUUPBCQU-UQYHSIEJSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
- WDCDAAMJNUHOIY-UHFFFAOYSA-N ethyl acetate;2-propan-2-yloxypropane Chemical compound CCOC(C)=O.CC(C)OC(C)C WDCDAAMJNUHOIY-UHFFFAOYSA-N 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000002032 methanolic fraction Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- XGZVNVFLUGNOJQ-UHFFFAOYSA-N n,n-dimethylformamide;ethyl acetate Chemical compound CN(C)C=O.CCOC(C)=O XGZVNVFLUGNOJQ-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- SQYNKIJPMDEDEG-UHFFFAOYSA-N paraldehyde Chemical compound CC1OC(C)OC(C)O1 SQYNKIJPMDEDEG-UHFFFAOYSA-N 0.000 description 1
- 229960003868 paraldehyde Drugs 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/14—Compounds having a nitrogen atom directly attached in position 7
- C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
- C07D501/18—7-Aminocephalosporanic or substituted 7-aminocephalosporanic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/14—Compounds having a nitrogen atom directly attached in position 7
- C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
- C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
- C07D501/22—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with radicals containing only hydrogen and carbon atoms, attached in position 3
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cephalosporin Compounds (AREA)
Abstract
This invention provides novel cephalosporin intermediates, 7 beta -amino-3-[(Z)-1-propen-1-yl]-3-cephem-4-carboxylic acid and esters thereof having the general formula <IMAGE> wherein the configuration of the 3-propenyl group is Z sometimes referred to as cis- and R is hydrogen or a conventional carboxy-protecting group, and acid addition salts thereof and the metal salts of the foregoing substance wherein R is hydrogen. These compounds are useful as intermediates for preparation of orally active cephalosporins. <IMAGE>
Description
SPECIFICATION
Cephalosphoranic acid derivatives
This application relates to 7-amino-3-propenyl cephalosporanic acid and esters thereof.
Description of the prior art
U.K. Patent Specification 1,342,241 published January 3, 1974 (corresponding U.S. Patent Nos.
3,769,277, and 3,994,884, granted October 30, 1973, and November 30, 1976) discloses the Compound VI but there is no description of 7-amino-3-[(Z)-1-prnpen-1-yI]-3-cephem-4-carboxyIic acid as an intermediate in the preparation thereof.
U.S. Patent No. 4,409,214 patented October 11, 1983 discloses the preparation of Compound VII via the
Wittig reaction on diphenylmethyl 7-benzylideneamino-3-triphenyl-phosphoniomethylceph-3-em-4-car- boxylate in Preparations 38 and 39, but there is no description of 7(3-amino-3-[(Z)-1-prnpen-1-ylj-3-ce- phem-4-carboxylic acid, or of an other 3-(1-propen-1-yl)cephalosporin compound.
U.S. Patent No. 4,110,534 patented April 29, 1978 is particularly concerned with preparation of compounds such as VI and VII by the Wittig reaction. Refer particularly to columns 8, 9, and 49 (Example 21).
H. O. House et al. Jour. Org. Chem. 29, 3327-3333 (1964) have studied the effect of solvents and additives including lithium salts on the proportions of cis- and trans- olefins produced in the Wittig reaction with aldehydes.
Summary of the invention
This invention relates to cephalosporin intermediates having Formula I, the synthetically useful acid addition and metal salts thereof, and to processes for their preparation.
In the compounds of Formula I, the configuration of the 3-propenyl group is Z- or cis-. R is hydrogen or a conventional carboxy-protecting group. The latter expression refers to protecting group of the sort conventionally used for amino or carboxyl groups in the synthesis of cephalosporin compounds. Suitable carboxyl protecting groups include aralkyl groups such as benzyl, p-methoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, and diphenylmethyl (benzhydryl), alkyl groups such as t-butyl; haloalkyl groups such as 2,2,2trichloroethyl, alkenyl groups such as allyl, 2-chloroallyl, alkoxymethyl groups such as methoxymethyl, 2 (trimethylsilyl)ethyl, trimethylsilyl, tert.-butyldimethylsilyl, tert.-butyldiphenylsilyl, and other carboxyl protecting groups described in the literature, for instance, in British Specification 1,399,086.We prefer to utilize carboxyl-protecting groups which are readily removed by treatment with acid, particularly benzhydryl or t-butyl. The acid addition salts and the metal salts of the foregoing substance where R is hydrogen are also part of the present invention.
The Z-, or cis- configuration of the 3-propenyl group is a critical aspect of the present compounds. This is the characteristic which determines the advantageous Gram negative antibacterial properties of the cephalosporin end products which are the subject of the parent application Serial No. 564,604.
The synthetically useful acid addition salts include the salts of Formula I with mineral acids such as hydrochloric acid, sulfuric acid and phosphoric acid, with organic sulfonic acids such as p-toluenesulfonic acid and other acids known and used in the cephalosporin arts.
Those substances of Formula I wherein R is hydrogen also form metal salts. Synthetically suitable metal salts include the sodium, potassium, calcium, magnesium, aluminum, and zinc salts.
The most preferred compounds of the invention are:
1. Diphenylmethyl 7ss-amino-3-[(Z)-1 -propen-1 -yl]-3-cephem-4-carboxylate.
2. Diphenylmethyl 7p-amino-3-[(Z)-l-propen-l -yl]-3-cephem-4-carboxylate hydrochloride.
3. Dip henylmethyl 7p-a mino-3-[(Z)- 1 pen-I -yl]-3-cephem-4-carboxylate sulfate.
4. Sodium 7t3-amino-3-[(Z)-1-propen-1-yIi-3-cephem-4-carboxylate.
5. Potassium 7ss-am ino-3-[(Z)-1 -propen-1 -yl]-3-cephem-4-carboxylate.
6. 7ss-Amino-3-[(Z)-1 -propen-1-yl]-3-cepehm-4-carboxylic acid.
Detailed description of the invention
In another aspect, this invention relates to processes for the preparation of the compounds of Formula
I. Preferred procedures are shown in Reaction Schemes 1 and 2.
In reaction Scheme 1, the diphenylmethyl group is shown as the preferred carboxy-protecting group. It will be appreciated by those skilled in the art that other carboxyl-protecting groups, well-known in the art, may be used.
In the Wittig reaction of Compound III with acetaldehyde, we have found that addition of an appropriate lithium halide such as lithium chloride, lithium bromide or lithium iodide improves the yield and proportion of UE isomer of the reaction product Ila. The reaction is preferably carried out with 5 to 15 chemical equivalents, preferably 10 equivalents of lithium bromide.
Methylene chloride is the preferred reaction medium preferably containing a cosolvent such as dimethylformamide or isopropanol in minor proportions of from about 1/10 to 1/3 part by volume per part of methylene chloride. Reaction temperatures in the range of -10 C to +25"C are appropriate with 0 to 25"C being preferred. The Wittig product Ila is extracted into a suitable organic solvent such as ethyl acetate and the extract is treated with Girard's reagent T to afford the 7-aminoceph-3-em compound of the present invention, la. Refer to Procedure 3 hereof. Subsequent treatment of la with trifluoroacetic acid (TFA) yields 7ss-amino-3-[(Z)-1-propen-1-yl]-3-cephem-4-carboxylic acid (Ib, Procedure 7) in the ratio of Z/E = 9/1.Acylation of Ib with p-hydroxyphenylglycine by a conventional acid chloride method or an activated ester method yields the orally effective cephalosporin V of the parent application Serial No.
564,604.
An alternative route, acylation of 7ss-amino-3-propen-1-yi cephalosporin ester la with the N-BOC (tert.butoxycarbonyl) blocked p-hydroxyphenylglycine in the presence of DCC (dicyclohexylcarbodiimide) and followed by deblocking with TFA (trifluoroacetic acid) also yields the cephalosporin V.
Scheme 1 Scheme 2 PhcE=N0}JLS=PPh3 PhcH2coNHy7 S CH=PPh3 COOCHPh2 III O COOCHPh2 COOCHPh2 Procedure 3 | 10 VIII Procedure 10 PhCII= pC::ICBCal I PhCH2CONH S t F N < CH=CH-CH3 J v4 CH=CHCH3 - COOCHPh2 ITa 0 COOCHPh2 COOCHPhZ Procedure 3 aProcedure 11 Ix Y \L H2 CH=CBiCR3 COOCHPhZ Procedure 5 COOCHPh2 / \ Procedure 7, or 8 Ia Procedure 7, or 8 HO C1HCONH H2N NHBOC HzCH=CH-CH3 P < CH=CH-CH3 Iv coOcHPh2 COOR Tb Procedure 6 , 'Yrocecure 9 \ Procedure 9 HO 5 CHCONEL O < H=CH-CH3 V COOH
BMY-28100
Description of specific embodiments
The following abbreviations which appear in the experimental procedures have the meaning indicated below:
Ph = phenyl
BOC = COOC(CHs)3 DCC = dicyclohexylcarbodiimide
TFA = trifluoroacetic acid
EtOAc = ethyl acetate
DMF = dimethylformamide
Procedure 1 Diphenylmethyl 7-benzylideneamino-3-triphenylphosphoniomethyl-3-cephem-4-carboxyjate chloride
To a suspension of diphenylmethyl 7-amino-3-chloromethyl-3-cephem-4-carboxylate hydrochloride (200 g, 0.44 mole) in CH2CI2 (940 ml) was added 1 N NaOH (440 ml) at room temperature. The mixture was shaken for 10 minutes and the organic layer was separated. To this organic layer were added MgSO4 (75 g) and benzaldehyde (51 g), 0.48 mole) and the mixture was allowed to stand for 3 hours at room temperature. The reaction mixture was filtered and the insolubles were washed with CH2CI2 (200 ml). To the combined filtrate and washings was added triphenylphosphine (126 g, 0.48 mole). The mixture was con centrated to about 400 ml under reduced pressure and allowed to stand for 4 days. The resulting viscous oil was diluted with ethyl acetate (1 I) and triturated to separate the title compound, a pale yellow crystalline powder which was collected by filtration and dried in vacuo Yield 322 g (96%). M.p. 1851900C (dec.).
IR: vmsarx cm-1 1780, 1720, 1630.
UV: #maxCH2Cl2 nm () 260 (24100).
Procedure 2
Diphenylmethyl 7-benzylideneamino-3-[(triphenylphosphoranylidene)-methyl]-3-cephem-4-carboxy- late (III)
A mixture of diphenylmethyl 7-benzylideneamino-3-triphenylphosphoniomethyl-3-cephem-4-carboxy- late chloride (322 g, 0.42 mole) and 5 N Na2CO3 (252 ml) in CH2C12 (1.6 I) was stirred vigorously for 15 minutes at room temperature. The organic layer was separated, dried over MgSO4 and concentrated to about 500 ml of volume. The concentrate was diluted with acetone (1 I), with stirring, to give a light yellow crystalline powder which was collected by filtration to yield 237 g (78%) of 3, melting at 195~198 C (dec.).
IR: V,,KBj cm 1 1770, 1620.
UV: XCH2sCI2 n m (E) 254 (23000), 389 (22000).
NMR: bcDc13 ppm 2.56 & 3.16 (2H, ABq), 5.00 (1H, d, J=4 Hz), 5.23 (1H, d, J=4 Hz), 5.47 (1H, d, J=22 Hz), 6.95 (1H, s), 7.2-7.8 (30H, m), 8.55 (1H, s).
Procedure 3
Diphenylmethyl 7-amino-3-((Z)- 7-propen- l-yl)-3-cephem-4-carboxylate hydrochloride (la hydrochloride)
To a cold solution of LiBr (19 g, 216 m moles) in a mixed solvent of dry dimethylformamide (100 ml) and CH2CI2 (300 ml) were added acetaldehyde (20 ml, 360 m moles) and diphenylmethyl 7-benzylide neamino-3-[(triphenylphosporanylidene)methyl]-3-cephem-4-carboxylate (III) (15 g, 20 m moles) at -5"C.
The mixture was allowed to stand for 20 hours at -5~-10 C and then 5 hours at room temperature. The resulting light brown solution was concentrated at ca. 100 ml of volume in vacuo and added to a two layer solvent of ethyl acetate (400 ml) and H2O (400 ml). The upper layer was separated and diluted with isopropyl ether (400 ml). Silica gel (Wako gel C-100, 40 g) was added to the mixture. The mixture was shaken for 5 minutes and filtered through a pad of diatomaceous filter aid. Insolubles were washed with a mixed solvent of ethyl acetate-isopropyl ether (1/1, 200 ml). The combined filtrate and washings were concentrated to ca. 400 ml of volume. A 0.5 M Girard reagent T solution in methanol (60 ml) and acetic acid 96 ml) was added to the above concentrate and the mixture was stirred for 15 minutes at room temperature.The mixture was evaporated to ca. 200 ml of volume, washed with H2O (200 ml), sat. aq.
NaHCO3 (3x20 ml) and brine (20 ml) successively, dried over MgSO4, treated with charcoal and concentrated to ca. 50 ml. To the concentrate was added N HCI in methanol (40 ml) at room temperature and left standing for 15 minutes. The mixture was evaporated to ca. 30 ml and diluted by addition of ether i300 ml). The precipitate was collected by filtration and dried over P205 to give 7.9 g of light yellow powder. A solution of the powder (7.3 g) in a mixed solvent of methanol (80 ml) and ethyl acetate (80 ml) was treated with charcoal, concentrated to ca. 100 ml, seeded with crystalline hydrochloride of the title compound, diluted slowly with ether (80 ml) and stirred for 1 hour. The separated colorless crystals were collected by filtration and dried over P205 in vacuo to give 6.3 g (71%) of the title compound.This product is a mixture of the isomers Z and E with reference to the propenyl moiety at the 3 position (Z/E=9/1 by HPLC) (Lichrosorb RP-18, 80% CH3OH-pH 7.2 phosphate buffer, 254 nm, 1 ml/min.).
IR: VK3,' cm-l 2850, 1785, 1725.
UR: Xma ZH nm (E I,) 287 (173).
NMR: cDMs ds ppm 1.47 (27/10H, d-d, J=7, 2 Hz, =CHCH3, cis, 1.74 (3/10H, d, J=7 Hz, =CHCH3, trans), 3.47 & 3.8 (each 1H, d, J=16 Hz), 5.13 1H, d, J=4.5 Hz, 6-H), 5.23 (1H, d, J=4.5 Hz, 7-H), 5.62 (1H, d-q, J=10 & BR< 7 Hz, 3-CH=CH), 6.24 (1H, d-d J=10 & 2 Hz, 3-CH), 6.81 (1H, s, CHPH2), 7.35 (10H, m, Ph-H).
Procedure 4 Diphen ylmethyl 7-amino-3-((Z)- 1-propen- 1-yl)-3-cephem-4-carboxylate (Ia) To a stirred suspension of the hydrochloride of diphenylmethyl 7-amino-3-((Z)-1-propen-1-yl)-3-cephem4-carboxylate (5 g, 11.3 m moles) in H2O (20 mol) and ethyl acetate (40 ml) was added NaHCO3 until the pH of the mixture became 8. The organic layer was washed with sat. aq. NaCI (5 ml), dried over MgSO4 and concentrated to ca. 20 ml of volume. The resulting solution was diluted with isopropyl ether (10 ml) and seeded with crystalline la. Additional isopropyl ether (30 ml) was added slowly to the mixture with stirring.After 15 minutes the separated colorless crystals were collected by filtration, washed with isopropyl ether (10 ml) and dried over P2Os in vacuo to give 4.3 g (94%) of the title compound (Z/E=9/1 by
HPLC) (Lichrosorb RP-18 80% methanol - pH 7.2 phosphate buffer, 254 nm, 1 ml/min).
IR: vmsarx cm- 3450, 1765, 1730.
UV: Am H nm (E:,) 289 (185).
NMR: bcDc13 ppm 1.43 (3H, d-d, J=2 & 7 Hz, CH=CHCH3), 1.66 (2H, br, s, disappeared by D2O, NH2), 3.23 & BR< 3.55 (each 1H, d, J=17 Hz, 2-H), 4.73 (1H, d, J=4.5 Hz, 6-H), 4.96 (1H, d, J=4.5 Hz, 7-H), 5.46 (1H, d-q,
J=10 & 7 Hz, 3-CH=CH), 6.06 (1H, br, d, J=10 Hz, 3-CH), 6.94 (1H, s, CHPh2), 7.3 (10H, m, Ph-H).
Procedure 5
Diphenylmethyl 7-l(D)-a-(t-butoxycarbonylamino)-a (4-hydroxyphenyl)acetamidoj.3-((Z)- 1-propen- 1-yl)-3- cephem-4-carboxylate (IV) A mixture of diphenylmethyl 7-amino-3-((Z)-1-propen-1-yI)-3-cephem-4-carboxylate (la) (4.2 g, 10.4 m moles), (D)-of-(t-butoxycarbonylamino)-a-(4-hydroxyphenyl)acetic acid (3.3 g, 12.5 m moles) and DCC (2.6 g, 12.5 m moles) in ethyl acetate (104 ml) was stirred for 1.5 hours at room temperature. The mixture was filtered and insolubles were washed with ethyl acetate (10 ml). The filtrate and the washings were combined and washed with sat. aq. NaHCO2 (3x5 ml), brine (5 ml), 10% HCI (5 ml) and brine successively, dried over MgSO4, treated with charcoal and filtered.The filtrate was concentrated to ca. 10 ml and diluted with n-heptane (20 ml). The precipitate was collected by filtration and dried over P205 in vacuo. Yield 7.8 g (90% pure, quantitative in weight) as colorless powder (Z/E=9/1 based on HPLC) (Lichrosorb RP-18, 80% methanol-pH 7.2 phosphate buffer, 254 nm, 1 ml/min.).
IR: vmsarx cm- 3400, 1790, 1720, 1690.
UV: XE nm (E 1yam) 278 (113), 289 (115), 295 (95).
NMR: bcDc13 ppm 1.3-1.45 (12H), m, BOC-H & =CH-CH3), 3.08 & 3.33 (each 1H, d, J=18 Hz, 2-H), 4.92 (1H, d, J=4.5 Hz, 6-H), 5.06 (1H, d, J=6 Hz. by D2O, CHN), 5.5 (1H, d-q, J=10 & 7 Hz, 3-CH=CH), 5.68 (1H, d-d, J=4.5 & Hz. d, J=4.5 Hz by D2O,7-H), 6.01 (1H, d,J=10 Hz, 3-CH), 6.65 & .08 (each 2H, d,J=8 Hz, 6.71 (1H, d, J=8 Hz, disappered by D2O, 7-NH2). 6.88 (1H, s, CHPh2), 7.3 (10H, m, Ph-H).
Procedure 6 BM Y-28 100; 7-[(D)-2-amino-2-(4-hydroxyphenyl)acetamido]-3-(propen-1-yl)-3-cephem-4-carboxylic acid (V)
A mixture of diphenylmethyl 7-[(D)-(t-butoxycarbonylamino)-(4-hydrnxyphenyl)acetamidoj-3-((Z)-1 propen-1-yl-3-cephem-4-carboxylate (IV) which was prepared in Procedure 5 (90% pure, 7.7 g, 10.6 m moles), anisole (7.7 ml) and trifluoroacetic acid (77 ml) was stirred for 1 hour at room temperature. The mixture was concentrated in vacuo. Toluene (50 ml) was added to the concentrate and the mixture was evaporated in vacuo. Ether (200 ml) was added to the residual oil. The separated solid was collected by filtration, washed with ether (20 ml) and dried over KOH in vacuo to afford 5.3 g of trifluoroacetic acid (TFA) salt of BMY-28100.The salt (5.3 g) was dissolved in H2O (100 ml), treated with charcoal and placed on a column packed with Diaion HP-20 (0.6 I). The column was washed with H2O (4 I) and eluted with 40% aqueous MeOH. The methanolic fractions (1.7 I) containing the desired product were collected and evaporated to ca. 20 ml of volume. The concentrate was diluted slowly with acetone (100 ml). The separated colorless crystalline powder was collected by filtration, washed with acetone (20 ml) and dried over P205 in vacuo to give 4 g (97%) of BMY-28100 (Z/E=9/1, Zwitterion) (Lichrosorb RP-18, 20% methanol - pH 7.2 phosphate buffer, 254 nm, 1 ml/min.
Procedure 7 7-amino-3-f(Z)- 1-propen- 1-yllceph-3-em-4-carboxylic acid, I b
To a stirred solution of 260 ml anisole and 1.38 1 of trifluoroacetic acid (TFA) cooled to 0 C was added 149.7 g (0.338 mole) of diphenylmethyl 7-amino-3-[(Z)-1-propen-1-yl]-3-cephem-4-carboxylic acid hydrochloride (0.338 mole, Procedure 3 or 11). The resulting slurry was then stirred at room temperature for 1 hour. Most excess of TFA was removed in vacuo on the rotary evaporation. The residual supernatant solution was decanted and the residual slurry was triturated with 1.5 1 of dry ether during 1 hour. The crystalline product was filtered and dried over P205 to give 87.24 g Ib trifluoroacetate.These 87.24 g of the trifluoroacetate were suspended and stirred into 900 ml of water (pH ca. 2.5). The mixture was cooled to +5"C and then adjusted to pH 0.6 with 12 N HCI. The yellow solution was charcoal treated and the slurry was filtered on a diatomaceous filter aid pad. The resulting solution was cooled to +5 C and the pH was adjusted to 2.0 with 20% NaOH. The suspension was kept 1 hour in a refrigerator to aid crystalli- zation. The crystals were collected, washed with 800 ml of water, 800 ml of acetone and vacuum dried at room temperature. Yield 69.4 g (85.5%). Contains 9.7% of trans isomer (determined by HPLC column
RP18 MERCK; H2(NH4)PO4, 0.1 mole 95 ml + CH3 CN 5 ml; detected at 290 nm).
Procedure 8 7-amino-3-((Z)- itprnpen 1-yl)-3-cephem-4-carhoxylic acid, I b
A solution of the phosphoranyl compound lil as produced by Procedure 2 (50.0 g, 68.7 m mole) in CH2Ci2 (500 ml) was mixed with a solution of lithium bromide (29.8 g), 343 m mole) in dry DMF (170 ml) containing a small amount of CH2CI2 (10 ml) and then with anhydrous acetaldehyde (39 ml, 687 m mole; prepared from paraldehyde and toluenesulfonic acid by distillation, according to the procedure of N.L.
Drake and G.B. Cook, Org. Syn. Col. Vol. II, p. 407). The mixture was placed in a sealed vessel and kept at 20"C for 2 days. The reaction mixture being evaporated, the residual liquid was diluted with EtOAc (800 ml), washed with water (3x300 ml) and a saturated NaCI solution (300 ml), and evaporated to give the blocked 3-propenyl solution (300 ml), and evaporated to give the block 3-propenyl derivative lla as foamy solid (34 g), which was used for the next reaction without further purification.
The crude Ila obtained above was treated with 98% formic acid (35 ml) and concentrated HCI (17 ml, 206 m mole) at room temperature for 1 hour. To the reaction mixture was added water (350 ml) to separate an oily layer, which was washed out with EtOAc (3x100 ml). The pH of the aqueous layer was adjusted to about 3 with 4N NaOH (ca. 65 ml) under stirring to give crystalline solid, which was collected by filtration and washed with water (50 ml) to afford the title compound (Ib, 9.7 g, 59%). HPLC [Lichrosorb
RP-18, 4x300 mm, MeOH: phosphate buffer (pH 7) = 15 : 85] showed that this product was an 83:17 mixture of Z and E isomers about the double bond of the 3-propenyl group. M.p. 200"C (dec.).
IR: VmaX (KBr) in cm- 3420, 1805, 1620.
UV: Xma, (pH 7 phosphate buffer) in nm (E) 283 (8900).
PMR: 3 (D2O + NaHCO3) in ppm 1.69 and 1.88 (3H, each d, J=6.0 Hz, Z and E of -CH=CH-CH3), 3.38 and 3.72 (2H, Abq, J=17 Hz, H-2), 5.18 (1H, d, J,=5.0 Hz, H-6), 5.51 (1H, d, H-7), ca. 5.8 (1H, m, -CH=CH-CH3) and 6.06 (1H, d, J=11 Hz, -CH=CH-CH3).
Anal. Calcd. for C,oH12N203S: C, 49.44; H, 5.03; N, 11.66; S, 13.34%.
Found: C, 50.20; H, 4.94; N, 10.93; S, 12.82%.
Procedure 9 7-[rD)-2-amino-2-r4hydroxyphenyl)acetamido i-prop en- 1- 1-yl)-3-cephem-4-carboxylic acid, V Dimethylaniline (1.7 ml, 13.1 m mole), trimethylsilyl chloride (2.1 ml, 16.4 m mole) and triethylamine (TEA, 2.3 ml, 16.4 m mole) were added successivleyto a suspension of Ib produced by Procedure 8 (1.58 g, 6.56 m mole) in CH2C12 (16 ml) under ice-cooling. The mixture was stirred at room temperature for 30 minutes. To the mixture was added portionwise under stirring D-p-hydroxyphenylglycyl chloride hydrochloride (1.46 g 6.56 m mole) and the reaction was monitored by HPLC [Lichrosorb RP-18, 4x300 mm,
MeOH: phosphate buffer (pH 7) = 25:75]. An additional amount of the glycyl chloride was added to the mixture 3 times at 15 minute intervals (291 mg each) to complete the acylation.After the addition of dry
MeOH (2.0 ml) containing dry DMF (0.1 ml), the resulting clear solution was neutralized with TEA (3.2 ml) to pH 6 and then diluted with CH2CI2 (30 ml) to give a precipitate, which was collected by filtration and washed with CH2Cl2 (10 ml) to give the title compound as the dimethylformamide solvate (2.39 g, yield 94%; ca. 50% pure; Z/E = 47:12 by HPLC).
Procedure 10
Diphenylmethyl 7-phenylacetamido-3-((Z)-propen- 1-yl)ceph-3-em-4-carboxylate, IX
A stirred solution of 18 1 of CCI4, methanol and 12 g p-benzoyl benzoic acid was cooled to 8"C 970 ml of acetaldehyde were added. The temperature of the resulting solution rose to +14 C. After five minutes, 588 g (0.7749 mole) of diphenylmethyl 7-phenylacetamido-3-[(triphenylphoranylidene)methyl]-3-cephem- 4-carboxylate was added. The cooling bath was removed and the mixture vigorously stirred for 4 hours at 35"C shaded from light under an N2 atmosphere until complete dissolution of the phosphorane had occurred.
The resulting solution was vacuum concentrated and the residue was dissolved in 2 1 of ethanol, and the solution was vacuum concentrated to a semi-crystallized residue which was slurried with 3 1 of ethanol.
The mixture was stirred for 2 hours at +5 C and let stand overnight, crystals were collected twice, washed with ethanol, and vacuum dried at room temperature. Yield 191 g (47%). M.p. 124-128 C contains 7.5% of trans isomer (determined by HPLC column Lichrosorb Si 60 5 iim Merck eluted with 85% toluene, 15% ethyl acetate.
Procedure ii Diphenylmethyl 7-amino-3-r6Z)-propen-1-yl)ceph-3-em-4carboxylate hydrochloride, la
To a stirred solution of 159.7 g (0.767 mole) of PCI5 in 2.8 I CH2CI2 were added 56.7 ml (0.700 mole) of pyridine in 280 ml CH2CI2 over a 20 minute period. Under a nitrogen atmosphere the slurry was cooled to 2"C while 256 g of IX produced by Procedure 10 (0.488 mole) was added.The mixture was stirred for 40 minutes and the resulting slurry was poured rapidly into a vigorously stirred solution of 1.4 1 of CH2CI2, and 209 ml (2.33 moles) of 1,3-butanediol at -20 C, so that the temperature did not rise above -5 C. The cooling bath was removed and after 45 minutes the temperature rose to 10"C and was held there for 35 minutes. Water (1.0 liter) was added and stirring continued for 5 minutes after which the layers were allowed to separate. The organic layer was washed with 600 ml HCI 2N and then 400 ml saturated brine.
The combined aqueous extracts were back-washed with 2 x 600 ml of CH2CI2 and combined with the original CH2CI2 extract.
The solution was dried over anhydrous MgSO4. The MgSO4 slurry was filtered and the MgSO4 washed with 2 x 500 ml CH2C12. The combined filtrates were concentrated in vacuo on the rotary evaporator to a volume of 2.4 liters and diluted with 2.5 liters of ethyl acetate. The solution was concentrated again to a volume of ca. 1.3 liters. The resulting crystal - slurry was filtered, washed with 3 x 300 ml ethyl acetate.
After air and vacuum drying over P2Os there was obtained 149.8 g of the title compound as beige crystals. Yield 69.3%.
Claims (13)
1. A compound of the formula
wherein the 3-propenyl group has the Z-configuration and R is hydrogen or a conventional carboxy-protecting group, and acid addition salts thereof and metal salts of the foregoing substance wherein R is hydrogen.
2. The compound of Claim 1 wherein R is a group selected from hydrogen, methoxymethyl, 2,2,2 trichloroethyl, 2-(trimethylsilyl)ethyl, t-butyl, benzyl, diphenylmethyl, o-nitrobenzyl, p-nitrobenzyl, trimethylsilyl, t-butyldimethyl-silyl, t-butyldiphenylsilyl, allyl, and 2-chloroallyl and acid addition salts thereof.
3. The compound of claim 1 or 2 wherein the acid addition salt is selected from of hydrochloride, sulfate, p-toluenesulfate, and phosphate.
4. The compound of Claim 1 or 2 wherein the metal salt is sodium, potassium, calcium, or aluminum salt.
5. The compound of Claim 2 which is diphenylmethyl 7(3-amino-3-[(Z)-1-prnpen-1-ylj-3-cephem-4-car boxylate and the hydrochloride thereof.
6. The compound of Claim 2 which is 7ss-amino-3-[(Z)-1-propen-1-yl]-3-cephem-4-carboxylic acid and the hydrochloride thereof.
7. The compound of Claim 4 which is sodium 7P-amino-3-[(Z)-l -propen-l -yl]-3-cephem-4-carboxylate.
8. The process for preparing a compound as claimed in Claim 1 which comprises reacting the intermediate of the formula
wherein R has the same meaning as in Claim 1, Ph is the phenyl group, with acetaldehyde in an inert organic reaction medium comprising dichloromethane, N, N'-dimethylformamide, isopropanol or a mixture thereof at a reaction temperature between 0 C and 25"C to provide a compound of the formula
and thereafter removing the benzylidene group or both the benzylidene group and the carboxy-protecting group and, if desired, separating the 3-(Z) and 3-(E) isomers to provide the compound of the formula
wherein R has the same meaning as in Claim 1.
9. The process of Claim 8 wherein the reaction with acetaldehyde is carried out in the presence of a lithium halide.
10. The process of Claim 9 wherein the lithium halide is lithium chloride, lithium bromide, or lithium iodide.
11. The process of Claim 9 wherein the lithium halide is lithium bromide.
12. A process as claimed in claim 8, substantially as described in the foregoing Experimental Procedures section.
13. A compound as claimed in claim 1, prepared by a process as claimed in claim 8, 9, 10, 11 or 12.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MYPI87002270A MY100694A (en) | 1985-04-22 | 1987-09-29 | Cephalosporanic acid derivatives. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72587185A | 1985-04-22 | 1985-04-22 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| GB8609661D0 GB8609661D0 (en) | 1986-05-29 |
| GB2173798A true GB2173798A (en) | 1986-10-22 |
| GB2173798B GB2173798B (en) | 1988-11-30 |
Family
ID=24916301
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB08609661A Expired GB2173798B (en) | 1985-04-22 | 1986-04-21 | Cephalosporanic acid derivatives |
Country Status (38)
| Country | Link |
|---|---|
| JP (1) | JPS61249989A (en) |
| KR (1) | KR860008189A (en) |
| CN (1) | CN1015714B (en) |
| AR (1) | AR242581A1 (en) |
| AT (1) | AT392072B (en) |
| AU (1) | AU589170B2 (en) |
| BE (1) | BE904646A (en) |
| CA (1) | CA1273629A (en) |
| CH (1) | CH671399A5 (en) |
| CS (1) | CS270435B2 (en) |
| CY (1) | CY1571A (en) |
| DD (1) | DD244557A5 (en) |
| DE (1) | DE3613365A1 (en) |
| DK (1) | DK163584C (en) |
| EG (1) | EG18001A (en) |
| ES (1) | ES8800236A1 (en) |
| FI (1) | FI84268C (en) |
| FR (1) | FR2580652B1 (en) |
| GB (1) | GB2173798B (en) |
| GR (1) | GR861065B (en) |
| HK (1) | HK106290A (en) |
| HU (1) | HU195223B (en) |
| IE (1) | IE59014B1 (en) |
| IT (1) | IT1228241B (en) |
| LU (1) | LU86402A1 (en) |
| MY (1) | MY100694A (en) |
| NL (1) | NL192205C (en) |
| NO (1) | NO164659C (en) |
| NZ (1) | NZ215717A (en) |
| OA (1) | OA08245A (en) |
| PT (1) | PT82436B (en) |
| SE (1) | SE500217C2 (en) |
| SG (1) | SG90890G (en) |
| SU (1) | SU1435155A3 (en) |
| YU (1) | YU43697B (en) |
| ZA (1) | ZA862985B (en) |
| ZM (1) | ZM4286A1 (en) |
| ZW (1) | ZW9086A1 (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0421219A3 (en) * | 1989-10-03 | 1992-05-13 | Bayer Ag | Process for the preparation of 7-amino-3-((z)-1-propenyl-1-yl)-3-cephem-4-carboxylic acid |
| EP0503453A3 (en) * | 1991-03-08 | 1992-12-09 | Biochemie Gesellschaft M.B.H. | New process for the production of cephalosporines and novel intermediates in this process |
| WO1993016084A1 (en) * | 1992-02-05 | 1993-08-19 | Biochemie Gesellschaft M.B.H. | Process for the purification of a 3-cephem-4-carboxylic acid derivative |
| EP0634415A2 (en) * | 1993-07-14 | 1995-01-18 | Sumitomo Chemical Company, Limited | Cephem compound, its production and its use for producing cephem antibiotics |
| AT399876B (en) * | 1992-02-05 | 1995-08-25 | Biochemie Gmbh | Purificn. of 7-amino-3-((z)-1-propen-1-yl)-3 -cephem-4-carboxylic acid - useful in prodn. of broadband antibiotics |
| WO2004033464A1 (en) * | 2002-10-08 | 2004-04-22 | Ranbaxy Laboratories Limited | Process for the preparation of (z)-isomer enriched 7-amino-3-propen-1-yl-3-cephem-4- carboxylic acid |
| WO2006048887A1 (en) * | 2004-11-01 | 2006-05-11 | Hetero Drugs Limited | A novel process for preparation of cefprozil intermediate |
| US7544797B2 (en) | 2003-10-30 | 2009-06-09 | Cj Cheiljedang Corporation | Processes for the preparation of cephem derivatives |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4708955A (en) * | 1985-06-24 | 1987-11-24 | Bristol-Myers Company | 3-(substituted)propenyl-7-aminothiazol-ylcephalosporanic acids and esters thereof |
| US4870168A (en) * | 1987-02-26 | 1989-09-26 | Bristol-Myers Company | 3-Unsaturated alkyl cephems from 3-triflyl cephems |
| JP4046708B2 (en) * | 2004-06-04 | 2008-02-13 | 明治製菓株式会社 | Method for producing 3-alkenylcephem compound |
| CN103183686B (en) * | 2011-12-30 | 2016-06-29 | 浙江新和成股份有限公司 | The preparation method of 7 beta-amino-7 α-methoxyl group-3-cephem compounds |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1342241A (en) * | 1970-01-23 | 1974-01-03 | Glaxo Lab Ltd | Cephalosporin compounds |
| US4110534A (en) * | 1970-01-23 | 1978-08-29 | Glaxo Laboratories Limited | Process for the preparation of 3-vinyl and substituted vinyl cephalosporins |
| US3769277A (en) * | 1970-01-23 | 1973-10-30 | Glaxo Lab Ltd | Preparation of delta3-4 carboxy cephalosporins having a 3-vinyl or substituted 3-vinyl group |
| US4065620A (en) * | 1971-06-14 | 1977-12-27 | Eli Lilly And Company | 3-(Substituted) vinyl cephalosporins |
| US4409214A (en) * | 1979-11-19 | 1983-10-11 | Fujisawa Pharmaceutical, Co., Ltd. | 7-Acylamino-3-vinylcephalosporanic acid derivatives and processes for the preparation thereof |
| US4520022A (en) * | 1983-01-28 | 1985-05-28 | Bristol-Myers Company | Substituted vinyl cephalosporins |
| AU566944B2 (en) * | 1983-10-07 | 1987-11-05 | Gist-Brocades N.V. | Preparation of 3-cephem derivatives |
-
1986
- 1986-03-21 FR FR8604051A patent/FR2580652B1/en not_active Expired
- 1986-04-07 NZ NZ215717A patent/NZ215717A/en unknown
- 1986-04-11 NO NO861430A patent/NO164659C/en unknown
- 1986-04-16 AU AU56168/86A patent/AU589170B2/en not_active Expired
- 1986-04-16 SU SU864027263A patent/SU1435155A3/en active
- 1986-04-17 EG EG219/86A patent/EG18001A/en active
- 1986-04-17 FI FI861634A patent/FI84268C/en not_active IP Right Cessation
- 1986-04-18 CA CA000507037A patent/CA1273629A/en not_active Expired - Lifetime
- 1986-04-18 AR AR86303699A patent/AR242581A1/en active
- 1986-04-21 PT PT82436A patent/PT82436B/en unknown
- 1986-04-21 DE DE19863613365 patent/DE3613365A1/en active Granted
- 1986-04-21 ZA ZA862985A patent/ZA862985B/en unknown
- 1986-04-21 IE IE104886A patent/IE59014B1/en not_active IP Right Cessation
- 1986-04-21 GB GB08609661A patent/GB2173798B/en not_active Expired
- 1986-04-21 HU HU861664A patent/HU195223B/en unknown
- 1986-04-21 DK DK182486A patent/DK163584C/en not_active IP Right Cessation
- 1986-04-21 SE SE8601825A patent/SE500217C2/en not_active IP Right Cessation
- 1986-04-21 DD DD86289446A patent/DD244557A5/en unknown
- 1986-04-21 CS CS862872A patent/CS270435B2/en not_active IP Right Cessation
- 1986-04-21 IT IT8620162A patent/IT1228241B/en active
- 1986-04-21 ZM ZM42/86A patent/ZM4286A1/en unknown
- 1986-04-21 LU LU86402A patent/LU86402A1/en unknown
- 1986-04-21 ZW ZW90/86A patent/ZW9086A1/en unknown
- 1986-04-21 CH CH1601/86A patent/CH671399A5/de not_active IP Right Cessation
- 1986-04-21 CN CN86102630A patent/CN1015714B/en not_active Expired
- 1986-04-21 OA OA58840D patent/OA08245A/en unknown
- 1986-04-21 BE BE0/216572A patent/BE904646A/en not_active IP Right Cessation
- 1986-04-21 ES ES554215A patent/ES8800236A1/en not_active Expired
- 1986-04-21 NL NL8601011A patent/NL192205C/en not_active IP Right Cessation
- 1986-04-22 JP JP61091419A patent/JPS61249989A/en active Granted
- 1986-04-22 YU YU659/86A patent/YU43697B/en unknown
- 1986-04-22 KR KR1019860003085A patent/KR860008189A/en not_active Ceased
- 1986-04-22 AT AT0106786A patent/AT392072B/en not_active IP Right Cessation
- 1986-04-22 GR GR861065A patent/GR861065B/en unknown
-
1987
- 1987-09-29 MY MYPI87002270A patent/MY100694A/en unknown
-
1990
- 1990-11-09 SG SG908/90A patent/SG90890G/en unknown
- 1990-12-18 HK HK1062/90A patent/HK106290A/en not_active IP Right Cessation
-
1991
- 1991-12-20 CY CY1571A patent/CY1571A/en unknown
Cited By (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5132419A (en) * | 1989-10-03 | 1992-07-21 | Bayer Aktiengesellschaft | Process for the preparation of 7-amino-3-((z)-1-propen-1yl)-3-cephem-4-carboxylic acid |
| EP0421219A3 (en) * | 1989-10-03 | 1992-05-13 | Bayer Ag | Process for the preparation of 7-amino-3-((z)-1-propenyl-1-yl)-3-cephem-4-carboxylic acid |
| EP0503453A3 (en) * | 1991-03-08 | 1992-12-09 | Biochemie Gesellschaft M.B.H. | New process for the production of cephalosporines and novel intermediates in this process |
| EP1103555A1 (en) * | 1992-02-05 | 2001-05-30 | BIOCHEMIE Gesellschaft m.b.H. | Process for the production of a 3-cephem-4-carboxylic acid derivative |
| WO1993016084A1 (en) * | 1992-02-05 | 1993-08-19 | Biochemie Gesellschaft M.B.H. | Process for the purification of a 3-cephem-4-carboxylic acid derivative |
| AT399876B (en) * | 1992-02-05 | 1995-08-25 | Biochemie Gmbh | Purificn. of 7-amino-3-((z)-1-propen-1-yl)-3 -cephem-4-carboxylic acid - useful in prodn. of broadband antibiotics |
| US5869648A (en) * | 1992-02-05 | 1999-02-09 | Biochemie Gesellschaft M.B.H. | Process for the purification of a 3-cephem-4-carboxylic acid derivative |
| US6333409B1 (en) | 1992-02-05 | 2001-12-25 | Biochemie Gesellschaft M.B.H. | Process for the purification of a 3-cephem-4-carboxylic acid derivative |
| EP1029864A1 (en) * | 1992-02-05 | 2000-08-23 | Biochemie GesmbH | Process for the purification of a 3-cephem-4-carboxylic acid derivative |
| US6136967A (en) * | 1992-02-05 | 2000-10-24 | Biochemie Gesellschaft M.B.H. | Process for the purification of a 3-cephem-4-carboxylic acid derivative |
| EP0634415A2 (en) * | 1993-07-14 | 1995-01-18 | Sumitomo Chemical Company, Limited | Cephem compound, its production and its use for producing cephem antibiotics |
| US5969131A (en) * | 1993-07-14 | 1999-10-19 | Sumitomo Chemical Company, Limited | Cephem compound, its production and its use for producing cephem antibiotics |
| WO2004033464A1 (en) * | 2002-10-08 | 2004-04-22 | Ranbaxy Laboratories Limited | Process for the preparation of (z)-isomer enriched 7-amino-3-propen-1-yl-3-cephem-4- carboxylic acid |
| US7544797B2 (en) | 2003-10-30 | 2009-06-09 | Cj Cheiljedang Corporation | Processes for the preparation of cephem derivatives |
| WO2006048887A1 (en) * | 2004-11-01 | 2006-05-11 | Hetero Drugs Limited | A novel process for preparation of cefprozil intermediate |
| US7629482B2 (en) | 2004-11-01 | 2009-12-08 | Hetero Drugs Limited | Process for preparation of cefprozil intermediate |
| EP2213676A1 (en) | 2004-11-01 | 2010-08-04 | Hetero Drugs Limited | A Novel process for preparation of cefprozil |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6034237A (en) | 3-imino-cephalosporins | |
| JPH0680064B2 (en) | New cephem compound | |
| MXPA96004353A (en) | Sistensis de cefalospori | |
| CZ280411B6 (en) | D-2-aminoacyl-3-(z)-propenylcephalosporin derivatives, process of their preparation and pharmaceutical compositions containing thereof | |
| CA1276929C (en) | Cephalosporin antibacterial agents | |
| GB2173798A (en) | Cephalosporanic acid derivatives | |
| EP0099553B1 (en) | Cephem compounds, process and intermediates for their preparation and pharmaceutical compositions containing them | |
| US5081116A (en) | Cephalosporin derivatives | |
| US4699979A (en) | 7-amino-3-propenylcephalosporanic acid and esters thereof | |
| GB2178032A (en) | Cephalosporanic acid derivatives | |
| GB2071664A (en) | Phosphonic acid derivatives of 7-((2-amino-4- thiazolyl)oximino)cephalosporins | |
| US4994454A (en) | Cepham derivatives | |
| US4943631A (en) | Process for cephem compounds | |
| US4699981A (en) | Cephalosporin derivatives | |
| KR870000528B1 (en) | Process for preparing 3-azidocephalosporins | |
| US3922268A (en) | 3-Halomethyl-{66 {hu 3-Cephalosporin esters | |
| US4334065A (en) | Cephalosporin intermediates | |
| US4841044A (en) | Cephalosporin derivatives | |
| GB1602876A (en) | Method for producing cepham compounds | |
| KR900004930B1 (en) | Process for preparing 7-amino -3-prophenyl cephalosporins | |
| EP0098615B1 (en) | 1-oxadethiacephalosporin compound and antibacterial agent containing the same | |
| GB2131799A (en) | Cephalosporin compounds | |
| HU205935B (en) | Process for producing cepheme-derivatives | |
| JPH01308288A (en) | Novel cephem compound and production thereof | |
| JPH01308285A (en) | Beta-lactam derivative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PE20 | Patent expired after termination of 20 years |
Effective date: 20060420 |